95% success rate of reaching pre-determined vascular target with no intraoperative complications presented during pre-clinical studies HINGHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY Robotic system, the first fully disposable robotic system, announced the system has surpassed its 100th catheterization […]
Tag: Microbot Medical
Gerry O’Sullivan, the Latest Member to Join Microbot Medical’s Scientific Advisory Board, to Leverage Extensive Interventional Radiology Experience to Progress the LIBERTY® Robotic System Through Regulatory, Clinical and Commercialization Phases
Widely Published Interventional Radiologist Has Earned Well-Regarded Reputation Working with Prestigious Medical Centers in the U.S. and Europe The addition of Professor O’Sullivan, the Clinical Director of Radiology for the Galway Clinic in Ireland, Expands the Company’s EU Presence. HINGHAM, Mass., March 23, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) continues to receive global […]
Microbot Medical Increases Presence in the EU with the Addition of Greece-based Key Opinion Leader Stavros Spiliopoulos, MD, PhD, EBIR-ES, FCIRSE, to its Scientific Advisory Board
Internationally Recognized and Awarded Interventional Radiologist Enhances Depth of Expertise as the LIBERTY® Robotic System Races Towards Regularity and Commercialization Objectives HINGHAM, Mass., March 13, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), which continues to experience a rising interest in the LIBERTY ® Robotic System, the first single-use endovascular robotic […]
Microbot Medical Leverages Recently Awarded Non-Dilutive Grant from the Israeli Government to Promote Marketing Activities Toward Commercialization of the LIBERTY® Robotic System
Engagement with Interventional Radiologists Reaches Highest Level Yet as Company Continues to Progress Through Regulatory and Clinical Phases; Company Seeking to Create Interest and Anticipation for When the System is Commercialized HINGHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic System, […]
Microbot Medical Expands its Geographic Presence to South America with the Addition of Francisco C. Carnevale, MD, PhD, FSIR to its Scientific Advisory Board
Increases Key Opinion Leaders to 13 Throughout the Americas, Israel, and Europe to Support the Company’s Next Regulatory and Commercialization Paths for the LIBERTY® Robotic System HINGHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), today announced that it has expanded its global presence to South […]
Microbot Medical’s Remote Controller for the LIBERTY® Robotic System Receives Design Patent Allowance in Japan
Allows Endovascular Procedure to be Performed from the Cath-Lab Control Room, Potentially Minimizing Radiation Exposure and Reducing Physical Strain for the Healthcare Providers Design Patent Complements Existing U.S. and European Design Patents as Feedback During Recent Meetings Continues to Support a Positive User Experience HINGHAM, Mass., Feb. 23, 2023 (GLOBE […]
Microbot Medical’s Novel LIBERTY® Robotic System Continues to be Validated with Latest U.S. Design Patent Allowance
Advanced Features of Remote Controller Specifically Developed to Deliver an Enhanced User Experience During Endovascular Procedures HINGHAM, Mass., Nov. 18, 2022 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), in a continuation of its efforts to create barriers and expand its global intellectual property portfolio for the LIBERTY® Robotic System, was […]
Microbot Medical Receives Additional Patent Allowance in Israel for the LIBERTY® Robotic System
Corresponding Application Previously Granted in the U.S. as the Company Continues to Create Global Barriers to Entry for its Novel Technology HINGHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) continues to aggressively protect its global intellectual property (IP) portfolio for the LIBERTY® Robotic System as an […]
Microbot Medical Completes GLP Animal Study for the LIBERTY® Robotic System
HINGHAM, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) announced a significant development milestone as it completed the GLP animal study for the LIBERTY® Robotic System, the first disposable robotic system being developed for endovascular procedures. The study was performed by a team of seasoned Key […]
Microbot Medical Enhances Strategic Focus on its Endovascular Solutions
Suspending Development of SCS and Evaluating Alternatives for SCS Assets HINGHAM, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) has announced that, following the recent acquisition of the endovascular assets of Nitiloop Ltd. along with other significant developments regarding the LIBERTY® Robotic System, including the commencement […]